ULTRALIFE CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ULTRALIFE CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.16M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $164.46M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $158.64M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $131.84M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $98.27M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $107.71M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $106.80M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $87.19M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $85.53M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $82.46M | Feb 8, 2018 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $78.84M | Mar 14, 2014 |
| FY2013 | Dec 31, 2012 | $101.66M | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | $135.74M | Mar 15, 2013 |
| FY2011 | Dec 31, 2010 | $166.82M | Mar 13, 2012 |
| FY2011 | Dec 31, 2009 | $154.30M | Mar 13, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.02M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $42.31M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $39.20M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $29.40M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $24.64M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $29.16M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $31.17M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $25.58M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $26.23M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $25.11M | Feb 8, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.90M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.31M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $7.20M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($119.0K) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($234.0K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.23M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $5.21M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $24.93M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $7.65M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.51M | Feb 8, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.90M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $9.97M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $9.48M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $129.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $35.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.70M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $7.37M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $6.56M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $6.48M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.76M | Feb 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.40M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $8.27M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $7.53M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $7.08M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $6.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $5.95M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $6.81M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $4.51M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $4.74M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $5.95M | Feb 8, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.34M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $24.08M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $22.19M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $22.19M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $17.78M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $17.51M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $16.99M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $14.52M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $15.02M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $15.40M | Feb 8, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.99M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $16.64M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $1.93M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($1.26M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.33M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $21.72M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($2.97M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $10.89M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $7.27M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.65M | Feb 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.87M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.93M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $2.55M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $1.68M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.81M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.10M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $6.28M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $4.19M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $1.39M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $1.22M | Feb 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.91M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $220.45M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $178.28M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $168.43M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $159.54M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $137.70M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $144.56M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $120.85M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $97.19M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $84.74M | Feb 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.78M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $86.26M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $52.85M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $52.03M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $41.80M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $20.78M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $34.81M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $16.39M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $18.14M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $16.88M | Feb 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.00M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $134.00M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $125.33M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $116.28M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $117.62M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $116.80M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $109.73M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $104.55M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $79.20M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $68.03M | Feb 8, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.38M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $45.01M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $37.57M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $37.43M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $38.07M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $27.02M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $26.75M | Feb 4, 2021 |
| FY2020 | Dec 31, 2018 | $20.11M | Feb 4, 2021 |
| FY2019 | Dec 31, 2017 | $20.46M | Feb 6, 2020 |
| FY2018 | Dec 31, 2016 | $19.97M | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.34M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($34.44M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($40.75M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($47.95M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($47.83M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($47.60M) | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | ($52.83M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | ($58.04M) | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | ($82.89M) | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | ($90.54M) | Feb 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.35M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.85M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $10.20M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $5.63M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.33M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $10.56M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | $7.14M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $25.58M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | $18.24M | Feb 15, 2019 |
| FY2015 | Dec 31, 2015 | $14.39M | Mar 2, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $55.00M | Apr 1, 2025 |
| FY2023 | Dec 31, 2023 | $25.75M | Mar 21, 2024 |
| FY2022 | Dec 31, 2022 | $21.50M | Mar 31, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (35) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 38 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 33 | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | 1 | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 8, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (35) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 38 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 32 | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | 1 | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Feb 8, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.66M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 16.63M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 16.35M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 16.35M | Mar 21, 2024 |
| FY2023 | Dec 31, 2021 | 16.14M | Mar 21, 2024 |
| FY2021 | Dec 31, 2020 | 15.96M | Mar 8, 2022 |
| FY2020 | Dec 31, 2019 | 15.87M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | 15.92M | Feb 6, 2020 |
| FY2018 | Dec 31, 2017 | 15.65M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 15.31M | Feb 8, 2018 |